PSMA and Beyond 2025 CA-IX in renal cell cancer (RCC), ZIRCON, kidney cancer, stage migration for RCC, REDECT trial, renal mass biopsy, girentuximab.

Investigators compared early oncologic outcomes by staging modality among men diagnosed with very high-risk prostate cancer.

Lantheus remains strong with PYLARIFY growth, Alzheimer’s potential, and solid financials despite stock volatility and risks.